organization · Reporting owner
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Braveheart Bio, Inc.
Report date August 07, 2026 · Filed August 10, 2026
Section 16 reporting ended · disclosed 2026-08-10. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,420,091 |
Reported balance
After 2026-08-07 transaction · row 1
1 source rowRow 1 · 2026-08-07 · Conversion · Acquired 7,420,091 · Balance 7,420,091 F1: The non-voting Series A preferred stock (the "Preferred Stock") of the Issuer are convertible into shares of Common Stock of the Issuer at the holder's election and have no expiration date. All shares of the Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock. |
| Non-voting Series A preferred stockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-08-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-07 · Conversion · Disposed 32,500,000 · Balance 0 F1: The non-voting Series A preferred stock (the "Preferred Stock") of the Issuer are convertible into shares of Common Stock of the Issuer at the holder's election and have no expiration date. All shares of the Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: The non-voting Series A preferred stock (the "Preferred Stock") of the Issuer are convertible into shares of Common Stock of the Issuer at the holder's election and have no expiration date. All shares of the Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock.
Kailera Therapeutics, Inc.
Report date April 20, 2026 · Filed April 22, 2026
Section 16 reporting ended · disclosed 2026-04-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,477,719 |
Reported balance
After 2026-04-20 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2026-04-20 · Conversion · Acquired 9,477,719 · Balance 9,477,719 F2: The Series A-2 convertible preferred stock and Series A-2 convertible non-voting preferred stock (collectively, the "Preferred Stock") of the Issuer are convertible into shares of Common Stock of the Issuer at the holder's election and have no expiration date. All shares of the Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock. |
| Common StockSEC Table I · non-derivative | Direct | 2,034,133 |
Reported balance
After 2026-04-20 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2026-04-20 · Conversion · Acquired 2,034,133 · Balance 2,034,133 F2: The Series A-2 convertible preferred stock and Series A-2 convertible non-voting preferred stock (collectively, the "Preferred Stock") of the Issuer are convertible into shares of Common Stock of the Issuer at the holder's election and have no expiration date. All shares of the Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock. |
| Series A-2 convertible preferred stockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-04-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-04-20 · Conversion · Disposed 4,968,789 · Balance 0 F2: The Series A-2 convertible preferred stock and Series A-2 convertible non-voting preferred stock (collectively, the "Preferred Stock") of the Issuer are convertible into shares of Common Stock of the Issuer at the holder's election and have no expiration date. All shares of the Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock. |
| Series A-2 convertible non-voting preferred stockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-04-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-04-20 · Conversion · Disposed 708,814 · Balance 0 F2: The Series A-2 convertible preferred stock and Series A-2 convertible non-voting preferred stock (collectively, the "Preferred Stock") of the Issuer are convertible into shares of Common Stock of the Issuer at the holder's election and have no expiration date. All shares of the Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectBy Hengrui (USA) Ltd. | 1 |
Reported balance
Holding disclosure · report date 2026-04-20 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1 F1: The reported securities are directly held by Hengrui (USA) Ltd. Hengrui (USA) Ltd. is a wholly-owned subsidiary of Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities are directly held by Hengrui (USA) Ltd. Hengrui (USA) Ltd. is a wholly-owned subsidiary of Jiangsu Hengrui Pharmaceuticals Co., Ltd.
F2: The Series A-2 convertible preferred stock and Series A-2 convertible non-voting preferred stock (collectively, the "Preferred Stock") of the Issuer are convertible into shares of Common Stock of the Issuer at the holder's election and have no expiration date. All shares of the Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 07, 2026 Filed Aug 10, 2026 14:03 UTC | Braveheart Bio, Inc. BRVE · Entity 4564 | ConversionNon-voting Series A preferred stock · Derivative | 32,500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-093140 · tm2622685-1_4seq1.xml · derivative · entry 2 Jiangsu Hengrui Pharmaceuticals Co., Ltd. · CIK 0002080343 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,420,091 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The non-voting Series A preferred stock (the "Preferred Stock") of the Issuer are convertible into shares of Common Stock of the Issuer at the holder's election and have no expiration date. All shares of the Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F1 · derivative.exercise_date: The non-voting Series A preferred stock (the "Preferred Stock") of the Issuer are convertible into shares of Common Stock of the Issuer at the holder's election and have no expiration date. All shares of the Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F1 · derivative.expiration_date: The non-voting Series A preferred stock (the "Preferred Stock") of the Issuer are convertible into shares of Common Stock of the Issuer at the holder's election and have no expiration date. All shares of the Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock. Read SEC document |
| August 07, 2026 Filed Aug 10, 2026 14:03 UTC | Braveheart Bio, Inc. BRVE · Entity 4564 | ConversionCommon Stock | 7,420,091 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-093140 · tm2622685-1_4seq1.xml · nonDerivative · entry 1 Jiangsu Hengrui Pharmaceuticals Co., Ltd. · CIK 0002080343 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,420,091 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The non-voting Series A preferred stock (the "Preferred Stock") of the Issuer are convertible into shares of Common Stock of the Issuer at the holder's election and have no expiration date. All shares of the Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 10:03 UTC | Kailera Therapeutics, Inc. KLRA · Entity 4435 | ConversionSeries A-2 convertible non-voting preferred stock · Derivative | 708,814 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-046276 · tm2612225-1_4seq1.xml · derivative · entry 5 Jiangsu Hengrui Pharmaceuticals Co., Ltd. · CIK 0002080343 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,034,133 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Series A-2 convertible preferred stock and Series A-2 convertible non-voting preferred stock (collectively, the "Preferred Stock") of the Issuer are convertible into shares of Common Stock of the Issuer at the holder's election and have no expiration date. All shares of the Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F2 · derivative.exercise_date: The Series A-2 convertible preferred stock and Series A-2 convertible non-voting preferred stock (collectively, the "Preferred Stock") of the Issuer are convertible into shares of Common Stock of the Issuer at the holder's election and have no expiration date. All shares of the Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F2 · derivative.expiration_date: The Series A-2 convertible preferred stock and Series A-2 convertible non-voting preferred stock (collectively, the "Preferred Stock") of the Issuer are convertible into shares of Common Stock of the Issuer at the holder's election and have no expiration date. All shares of the Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 10:03 UTC | Kailera Therapeutics, Inc. KLRA · Entity 4435 | ConversionSeries A-2 convertible preferred stock · Derivative | 4,968,789 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-046276 · tm2612225-1_4seq1.xml · derivative · entry 4 Jiangsu Hengrui Pharmaceuticals Co., Ltd. · CIK 0002080343 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,477,719 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Series A-2 convertible preferred stock and Series A-2 convertible non-voting preferred stock (collectively, the "Preferred Stock") of the Issuer are convertible into shares of Common Stock of the Issuer at the holder's election and have no expiration date. All shares of the Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F2 · derivative.exercise_date: The Series A-2 convertible preferred stock and Series A-2 convertible non-voting preferred stock (collectively, the "Preferred Stock") of the Issuer are convertible into shares of Common Stock of the Issuer at the holder's election and have no expiration date. All shares of the Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock. F2 · derivative.expiration_date: The Series A-2 convertible preferred stock and Series A-2 convertible non-voting preferred stock (collectively, the "Preferred Stock") of the Issuer are convertible into shares of Common Stock of the Issuer at the holder's election and have no expiration date. All shares of the Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 10:03 UTC | Kailera Therapeutics, Inc. KLRA · Entity 4435 | ConversionCommon Stock | 2,034,133 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-046276 · tm2612225-1_4seq1.xml · nonDerivative · entry 2 Jiangsu Hengrui Pharmaceuticals Co., Ltd. · CIK 0002080343 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,034,133 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The Series A-2 convertible preferred stock and Series A-2 convertible non-voting preferred stock (collectively, the "Preferred Stock") of the Issuer are convertible into shares of Common Stock of the Issuer at the holder's election and have no expiration date. All shares of the Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 10:03 UTC | Kailera Therapeutics, Inc. KLRA · Entity 4435 | ConversionCommon Stock | 9,477,719 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-046276 · tm2612225-1_4seq1.xml · nonDerivative · entry 1 Jiangsu Hengrui Pharmaceuticals Co., Ltd. · CIK 0002080343 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,477,719 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The Series A-2 convertible preferred stock and Series A-2 convertible non-voting preferred stock (collectively, the "Preferred Stock") of the Issuer are convertible into shares of Common Stock of the Issuer at the holder's election and have no expiration date. All shares of the Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.